Note: This is the Infectious Diseases Management Program COVID-19 site, which will house treatment related guidance going forward. For Hospital Epidemiology and Infection prevention's COVID-19 page, which houses guidelines around topics including disinfection, PPE, precautions, and other infection prevention related topics, please click here for Hospital Epidemiology and Infection Prevention's COVID-19 Page

• For treatment of patients with COVID-19 please refer to the IDSA Guidelines (NIH COVID-19 Guidelines are no longer being updated). In particular, Table 37 highlights recommended therapies for different levels of severity
• For guidance on pre-exposure prophylaxis (Pemivibart) for select populations refer to the attached document above
  • This guidance is also temporarily available here, will soon only be housed on this page
• For information on eligibility and ordering of outpatient remdesivir refer to the above attached file

------------------------------------------------------------------------------------------------------------------------------------------

 Remdesivir Ordering Guidance for Outpatient Adults

1. Remdesivir is given at the MZ or MB Infusion Center, 7 days a week
   1. Not given at Parnassus Infusion Center
2. Eligibility criteria: Patients must meet all of the below criteria:
   1. Symptomatic COVID-19 infection with symptom onset within 7 days
   2. High risk for progression to severe disease based on CDC risk factors https://www.cdc.gov/covid/risk-factors/
   3. Not eligible for nirmatrelvir-ritonavir (Paxlovid)
   4. Mild-moderate disease
      1. A provider visit is NOT included in the infusion visit.  If you would like your patient formally evaluated with exam, labs, x-ray, instead order REF778 or refer your patient to the SACC
3. ​​For ordering guidance see above attached document